The NMIBC curriculum will provide easily accessible and engaging educational material to enable urologists to explore the developments and management strategies for NMIBC, ranging from handling BCG-unresponsive cases to understanding the quality of life implications of radical treatments.
UROwebinar: NMIBC – BCG Unresponsive management in 2025 and new developments
This recording will focus on Bacillus Calmette-Guérin–unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC).
You can also enroll in the e-course “NMIBC – BCG Unresponsive management in 2025 and new developments” to gain 1 CME point.
Round table discussion – Radical cystectomy for NMIBC patients
In this round talbe discussion, moderator Assoc. Prof. Jonathan Aning joins with experts Dr. Carmen Mir and Dr. Marco Moschini, discussing radical cystectomy for NMIBC, the impact of treatments for NMIBC on quality of life, patient preference and what the future holds.
UROwebinar: NMIBC from intermediate to high risk: Current landscape and ongoing studies
This recording focuses on the evolving management of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). It aims to explain and explore the current definitions, treatment paradigms, and clinical dilemmas in daily practice.
You can also enroll in the e-course “NMIBC from intermediate to high risk: Current landscape and ongoing studies” to gain 1 CME point.
This educational activity has been funded by Ferring Pharmaceuticals. The educational programme of this online activity has been a collaboration with Ferring Pharmaceuticals, but independently developed and approved by the European Association of Urology.